Please join us for a discussion with Dr. Anthony Sabulski*, a leading physician and researcher of TA-TMA in HSCT patients.

Dr. Sabulski has been involved in essential research to identify patients at risk for this complication and to implement early interventions to improve TA-TMA associated transplant outcomes. View the webinar highlighting the latest treatment approaches aimed at improving the lives of post-transplant patients.

• Review past and present treatment approaches to TA-TMA.
• Focus on C5 inhibition as a TA-TMA treatment and how to optimize treatment outcomes.
• Discuss emerging TA-TMA therapies and future directions.

Length of Presentation: 1 hour 6 minutes

Presented by: 

• Dr. Anthony Sabulski, MD
  Assistant Professor of Clinical Pediatrics
  Bone Marrow Transplantation and Immune Deficiency
  The Cancer and Blood Diseases Institute
  Cincinnati Children’s Hospital Medical Center
• Dr. Steve Kleiboeker, PhD
  HCLD/TS/CC (ABB)
  Vice President, R & D
  Chief Scientific Officer Eurofins Clinical Diagnostics